Video Experimental Relacionado
Updated: Feb 24, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Antígeno prostático específico de membrana radioguiado en cáncer de próstata: una revisión narrativa
Piotr Chuchra1, Jakub Karwacki2,3, Akihiro Matsukawa4,5
1Department of Urology, Medical University of Silesia, Zabrze, Poland.
Introduction:
Prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) is being tested to personalize lymph node dissection at radical prostatectomy and in the salvage settings.
Material And Methods:
We conducted a narrative review using the MEDLINE database (via PubMed), selecting key publications on the intravenous administration of PSMA to investigate lymph node involvement during surgery.
Results:
This review provides an overview of the PSMA-RGS methodology and outcomes. The technique demonstrates high specificity, particularly in ex vivo settings, with a median ranging from 93.5% to 100%. However, sensitivity varies widely, with a median range of 50% to 100%, often limited by reduced detection of micrometastases. Detailed preoperative, perioperative, and oncological evaluations are summarized in tables.
Conclusions:
PSMA-RGS is feasible and safe in both primary and salvage settings. In appropriately selected patients, it may contribute to longer therapy-free survival (36 months) and prolonged biochemical recurrence-free survival (19 months).
